HEALTHY EXTRACTS INC.: Healthy Extracts Q2 2026 Net Revenue Up 113% to Record $2.1 Million, Driving Adj. EBITDA of $290,000 or $0.02 per Share

Healthy Extracts Inc. (OTCQB:HYEX) reported Q2 2026 net revenue up 113% to a record $2.1 million and adj. EBITDA of $290,000 ($0.02/share). Gross profit rose 145% to $1.5 million, with gross margin up to 70.3%. Results were attributed to the Gummy USA merger and the Imaraïs Beauty acquisition/partnership.

Original reporting
Published Aug 15, 2026, 12:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 15, 2026, 12:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$HYEX
Bullish
medium confidence
Mentioned
$HYEX
Relevance
7/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$HYEXBullishMed
01

Why it matters

The release combines quarterly financial results with operational milestones (Imaraïs partnership order, shipping to 4,000+ locations, and acquisition into a wholly owned subsidiary), which can influence near-term trading sentiment and expectations for subsequent quarters.

02

Market read

For HYEX, the key tradable update is the fresh Q2 print with acquisition-linked growth and a stated ambition for annualized revenue above $20M by year end.

03

What to watch

Net loss remains present in Q2 (-$129k), operating expenses rose 115%, and the $20M annualized target is aspirational rather than confirmed guidance.

Relevance 7/10Novelty 7/10Timing: pre-market/early session after Aug 14, 2026 release

Background

Healthy Extracts is an OTCQB nutraceutical formulation and precision-dose gummy manufacturer, recently expanding via Gummy USA merger (Oct 2025) and Imaraïs Beauty acquisition (May 2026).

Company-level read

Ticker impact

$HYEXBullishMedium confidence
Context

Healthy Extracts reports Q2 2026 net revenue up 113% to $2.1M and adj. EBITDA of $290k, citing Gummy USA merger and Imaraïs acquisition.

Expected impact

Likely positive bias for HYEX on follow-through interest, with volatility around whether the $20M annualized revenue goal is credible.

Evidence & confidence

The article provides fresh quarterly financial datapoints and ties them to specific consolidation events (merger and acquisition), which can re-rate growth expectations for a microcap OTC issuer.

Market effects

Highlights ongoing consolidation and B2B retail distribution expansion in nutraceutical gummies and functional wellness.

No clear regional macro linkage beyond the company’s Las Vegas base.

Mentions international retail presence via Imaraïs, but the disclosed impact is primarily US-focused.

Counterpoint

Record revenue growth may be heavily acquisition-driven, so organic demand and repeatability of margins could be weaker than headline growth implies.

Key entities

  • Healthy Extracts Inc.

    Reports Q2 2026 record net revenue and adjusted EBITDA, attributing growth to merger and acquisition integration.

  • Gummy USA

    Synergistic merger partner cited as a driver of revenue and margin improvement.

  • Imaraïs Beauty

    Acquired operating subsidiary; partnership order of nearly 4 million gummies and distribution into major retailers.

  • Sommer Ray

    Founder of Imaraïs Beauty, referenced as part of the brand’s market traction.

Related articles

$RIMEMed

Algorhythm Holdings Reports Third Quarter 2026 Financial Results

Algorhythm Holdings, Inc. (RIME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Algorhythm Holdings Reports Third Quarter 2026 Financial Results Company Completes Azure Energy Acquisition and Begins Strategic Restructuring Fort Lauderdale, FL, November 17, 2026 – Algorhythm Holdings, Inc. (the “Company”) (NASDAQ: RIME ), a diversified holding co

$PULMMed

Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger Merger with Eos SENOLYTIX expected to close by end of the year Framingham, Mass., November 17, 2026 – Pulmatrix, Inc. (“Pulmatrix”, the “Company” or “our”) (Nasdaq: PULM), a biopharmaceut